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Abstract: We studied the mechanism governing the delivery of nucleic acid-based drugs 
(NABD) from microparticles and nanoparticles in zero shear conditions, a situation occurring 
in applications such as in situ delivery to organ parenchyma. The delivery of a NABD molecule 
from poly(DL-lactide-co-glycolide) (PLGA) microparticles and stearic acid (SA) nanoparticles 
was studied using an experimental apparatus comprising a donor chamber separated from the 
receiver chamber by a synthetic membrane. A possible toxic effect on cell biology, as evaluated 
by studying cell proliferation, was also conducted for just PLGA microparticles. A mathemati-
cal model based on the hypothesis that NABD release from particles is due to particle erosion 
was used to interpret experimental release data. Despite zero shear conditions imposed in the 
donor chamber, particle erosion was the leading mechanism for NABD release from both 
PLGA microparticles and SA nanoparticles. PLGA microparticle erosion speed is one order of 
magnitude higher than that of competing to SA nanoparticles. Finally, no deleterious effects of 
PLGA microparticles on cell proliferation were detected. Thus, the data here reported can help 
optimize the delivery systems aimed at release of NABD from micro- and nanoparticles.
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Introduction
Nucleic acid-based drugs (NABD) represent a novel group of molecules with the 
potential to treat several different human diseases (Grassi et al 2004; Heidenreich 
2004). Because all are constituted by either RNA, such as small interfering RNAs 
(Hannon and Rossi 2004) or DNA, such as DNA enzymes (Breaker 1997), NABD are 
rapidly destroyed in physiological ﬂ  uids. Additionally, their hydrophilic nature makes 
cellular internalization a problematic step. Thus, to be effective in vivo, they need to 
be protected against degradation and the crossing of cellular membrane improved. 
A strategy to accomplish these requirements deals with the incorporation of NABD in 
microparticles made up of synthetic polymers (Jong et al 1997; Luo et al 1999; Wang 
et al 1999) or in polymeric nanoparticles (Hirosue et al 2001). The use of micro- and 
nanodevices is dictated by the fact that the smaller the particle diameter, the easier is 
the NABD cellular uptake (Luo and Saltzman 2000).
The mechanisms of NABD release from micro- or nanoparticles can be predicted to 
play a relevant role in the effectiveness of the delivery system. Thus, an investigation 
conducted both from the theoretical and experimental point of view in this sense is of 
potential relevance. Among others, a hydrodynamic condition corresponding to a virtual 
zero shear condition can be of interest for different applications such as trans-dermal 
delivery and the in situ delivery to organ parenchyma. The zero shear condition is 
realized when a particle suspension is put in contact with the surface of interest and no 
mixing is imposed on the suspension. For this purpose, we have used an experimental International Journal of Nanomedicine 2006:1(4) 524
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apparatus made up of a donor chamber separated from the 
receiver chamber by a synthetic membrane. The donor 
chamber hosts an unstirred particle suspension while the 
receiver chamber hosts a pure fluid undergoing proper 
mixing. A mathematical model based on the hypothesis 
that NABD release from particles is due to particle erosion 
is used to interpret experimental data. This experimental 
set up enables the predominant mechanism governing the 
delivery under our conditions to be determined. In particular, 
in this work we focused on the study, in conditions of virtual 
zero shear, of the delivery kinetics of single-stranded DNA 
oligonucleotide, chosen as a prototype for NABD, from 
poly(DL-lactide-co-glycolide) (PLGA) microparticles and 
stearic acid (SA) nanoparticles. Additionally, for just PLGA 
microparticles, we explored the possible toxic effects of 
PLGA on cultured humans cells, evaluated by studying the 
effects on cell proliferation.
DNA-based molecules instead of RNA-based molecule 
(such as siRNAs and ribozymes) were chosed because of 
their better stability and lower cost.
Materials and methods
Cell culture
Human coronary smooth muscle cells (CSMC), purchased 
from CellSystems Biotechnologies GmbH, had no more than 
9 doublings when used in the experiments. The cells were 
grown in a medium (deﬁ  ned as complete medium) containing 
one third Smooth Muscle Cell Basal Medium (Promocell, 
Heidelberg, Germany), one third Waymouth Medium MB 
752/1, and one third Nutrient Mixture F12 supplemented with 
15% fetal calf serum (FCS) and 1% penicillin/streptomycin 
(Life technologies, Gaithersburg, MD, USA). CSMCs were 
kept in a moist atmosphere with 5% CO2 at 37°C.
Cell proliferation assays
2.6 mg of PLGA micro-particles were incubated with 7x104 
CSMC in complete growth medium for 24 hours. As control, 
cells treated with 12 μg of a cationic liposome commonly used 
to transfect CSMC (CellFectin, Invitrogen) (Grassi et al 2005) 
and non-treated cells, were evaluated in parallel. Ten hours 
before harvesting, cells were pulsed with bromodeoxyuridine 
(BrdU) at a concentration of 10 μM. Afterwards, cells were 
prepared for BrdU staining as it follows. Cells were trypsin-
ized and resuspended in 100 μL of ice cold 70% ETOH for 
20 min. After washing with PBS containing 0.5% bovine 
serum albumin (BSA), cells were treated with 2M HCl and 
0.5% BSA for 20 min. After a further washing step, cells were 
resuspended in 0.1 M sodium borate pH 8.5 for 2 min and 
washed again. From each sample, an aliquot was withdrawn 
and incubated with 6 μL of R-phycoerythrin conjugated 
mouse IgG1 isotype control (PharMingen International) for 
20 min. The remaining part of each sample was incubated with 
6 μl of R-phycoerythrin conjugated anti-BrdU monoclonal 
mouse antibody (PharMingen International) for 20 min. 
After a ﬁ  nal washing step, cells were resuspended in PBS 
containing 0.5% BSA and, for cell cycle analysis only, 8 μL of 
7-Amino-Actinomycin D (Via-PROBE, Becton Dickinson). 
Samples were analyzed by ﬂ  ow cytometry (FACScalibur, 
Becton Dickinson) using the CellQuest software.
DNA oligonucleotide synthesis
The DNA oligonucletide here used was chemically synthe-
sized (Eurogentec, Herstal Belgium) with a length of 38 
nts (GGAUCAGG CUGAUGAGUCCGUGAGGACGAA 
AGCAGGGG 3'), resembling the sequence of a ribozyme 
proved by us (Grassi et al 2005) to be effective in cultured 
CSMC.
Microparticle preparation
Microparticles were prepared according to the double 
emulsion evaporation method proposed by Nihant et al 
(1994). Primary emulsion was realized by mixing (high 
shear mixer; Silverson, UK) 1 cm3 of phosphate buffer 
solution at pH 7.4 (PBS: Na2HPO4 4.76 g; KH2PO4 0.38 g; 
NaCl 16 g into 2L of deionized water) containing 1000 μg 
of single-stranded DNA oligonucleotide, with 5 g of PLGA 
(Boehringer Ingelheim) solution in methylene chloride (MC; 
BDH Italy, Milano) and a stabilizing agent as Poloxamer 
F68 (Pluronc F68, BASF, Germany) (solution composition: 
PLGA 9% w/w, MC 90% w/w, PF68 1% w/w). Secondary 
emulsion was obtained by dispersing the primary emulsion, 
under stirring (6 blades impeller at 700 rpm) and sonication 
for 30 min, into a 100 cm3 of a 2.5% w/v polyvinyl alcohol 
aqueous solution (PVA, Sigma, St Louis, USA). Temperature 
was ﬁ  rstly maintained at 0°C for half an hour, then increased 
to up to 20°C and kept constant for 2 hours in order to allow 
solvent (MC) removal. Microparticles were ﬁ  nally collected 
by centrifugation/ﬁ  ltration (0.2 μm regenerated cellulose 
membrane Sartorius®, Germany), washed with water, and 
dried under vacuum at 25°C. Theoretical single-stranded 
DNA oligonucleotide concentration in dry microparticles 
was 2000 μg/cm3. Microparticle diameter was measured 
according to photon correlation spectroscopy (PCS N4Plus 
Beckman-Coultar; Fullerton, CA, USA) and SEM pictures 
were taken with EVO 40 microscope (LEO, Cambridge, UK) 
to conﬁ  rm these results.International Journal of Nanomedicine 2006:1(4) 525
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Nanoparticle preparation
Nanoparticle preparation was based on the formation of an 
oil-in-water (O/W) microemulsion. O/W microemulsions 
were prepared by mixing 300 mg of lipid blend components 
stearic acid (BDH, UK)/Labraﬁ  l® CS2125 (glycerol oleate-
linoleate PEG 6 complex; Gatefossé, France) (weight ratio 
95:5) with 100 mg of surfactant (sodium taurodeoxycholate 
acid; Sigma). 1 cm3 of deionized water plus 0.1 cm3 of 
cosurfactant (N-Buthanol BDH-UK) and 1000 μg of single-
stranded DNA oligonucleotide constituted the aqueous 
phase that was added to the oil phase. 0.4 cm3 of non-ionic 
surfactant (Tween® 80; Sigma) were added to the emulsion 
until the formation of a transparent, homogeneous system. 
All components and the microemulsion preparation were 
maintained at temperatures above the melting point of the 
lipid phase (65–70°C). Microemulsion was subsequently dis-
persed (dilution 1:50) in cold deionized water for 30 min and 
then at 20°C for 1 hour. Microemulsion stirring was ensured 
by a 6-blade impeller at 500 rpm. Samples of suspended 
nanoparticles were then washed 3 times by tangenzial ﬂ  ow 
ultraﬁ  ltration (Minitan-S Ultraﬁ  ltration System; Millipore, 
USA) to eliminate surfactant and cosurfactant residual. 
Then, dry nanoparticles were collected by lyophilization 
and stored at 4°C. The theoretical single-stranded DNA 
oligonucleotide concentration in dry nanoparticles was 
2500 μg/cm3. Nanoparticle diameter was measured using 
particle size analyzer (photon correlation spectroscopy PCS) 
and SEM microscopy in order to conﬁ  rm the results.
Release experiments
All release experiments were done in the Franz cell depicted 
in Figure 1. Basically, the cell is a double-walled beaker 
characterized by a top donor chamber (5 cm3) separated 
from the receiver chamber (22 cm3) by a synthetic membrane 
(polysulphon, 104 cut off, Millipore). Lower and higher 
membrane cut off was discharged, as lower cut off implied 
a lower membrane permeability reﬂ  ecting very long release 
experiments. On the contrary, higher cut off membranes also 
allowed also the permeation of part of the materials constitut-
ing our particles and this caused some interference problems 
in the UV determination of DNA concentration.
Although the donor chamber was not mixed, a magnetic 
stirrer ensured receiver chamber mixing (500 rpm). System 
thermostatic conditions (37°C) were ensured by means of a 
heating jacket (see Figure 1). Single-stranded DNA oligonu-
cleotide concentration in the receiver chamber was monitored 
via an on-line computer-managed Perkin Elmer Lambda 
Series UV spectrophotometer (wavelength λ = 255 nm,
cell path = 1 cm). A peristaltic pump was used for system 
liquid circulation (28 cm3/min). In this experimental set up 
single-stranded DNA oligonucleotide loaded particles expe-
rienced virtually zero shear conditions during release. Three 
different kinds of release experiments were performed. In the 
ﬁ  rst kind, the donor chamber was ﬁ  lled by 4 cm3 of a PBS 
solution at pH 7.4 characterized by a single-stranded DNA 
oligonucleotide concentration equal to 10 μg/cm3, while 
the receiver chamber contained 22 cm3 of a PBS solution 
pH 7.4. This experimental conﬁ  guration served to estimate 
single-stranded DNA oligonucleotide diffusion coefﬁ  cient 
through the polysulphon membrane. In the other two kinds of 
release experiments, the donor chamber was ﬁ  lled by 5 cm3 
buffer pH 7.4 solution containing 100 mg of particles. The 
receiver chamber always contained 22 cm3 of PBS solution 
pH 7.4. These tests served to the evaluation of particle 
erosion speed. All release tests were performed in duplicate 
and the experimental standard error never exceeded 15% of 
experimental mean.
membrane
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Figure 1 Schematic representation of the experimental apparatus used for release 
experiments (Franz cell apparatus). The synthetic membrane separates the donor 
chamber (not mixed) from the receiver chamber where mixing is ensured by a 
magnetic stirrer.International Journal of Nanomedicine 2006:1(4) 526
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Modeling
In the light of the programmed experimental tests, 2 math-
ematical models need to be examined. The ﬁ  rst refers to 
single-stranded DNA oligonucleotide permeation across the 
synthetic membrane assuming that the donor chamber con-
tains a single-stranded DNA oligonucleotide PBS solution of 
known initial concentration. The second refers to the simul-
taneous single-stranded DNA oligonucleotide release from 
particles and permeation across the synthetic membrane.
Assuming that the synthetic membrane thickness is very 
small, it follows that a linear concentration proﬁ  le of the 
single-stranded DNA oligonucleotide always holds inside 
the membrane (Grassi and Colombo 1999). In addition, we 
assume that no interactions between single-stranded DNA 
oligonucleotide and synthetic membrane occur (Coviello 
et al 2005; Grassi and Grassi 2005). Thus, the single-stranded 
DNA oligonucleotide concentration in the receiver chamber 
Cr can be evaluated according to the following equations:
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where Cr, Vr, and Cd, Vd are, respectively, single-stranded 
DNA oligonucleotide concentration and volume of the 
receiver and donor chamber, t is time, S and LM are, respec-
tively, membrane surface and thickness, kd and kr are, 
respectively, single-stranded DNA oligonucleotide partition 
coefﬁ  cients on the donor and receiver chamber side, Cd0 is the 
initial single-stranded DNA oligonucleotide concentration 
in the donor chamber, X is the abscissa, and D is the single-
stranded DNA oligonucleotide diffusion coefﬁ  cient in the 
membrane. Eq.(1) is a kinetic equation stating that the time 
variation of the single-stranded DNA oligonucleotide mass 
(VrCr) in the receiver solution depends on the concentration 
gradient (( )/ ), kC kC L dd rr M −  the diffusion coefﬁ  cient (D), 
and the membrane area (S) available for permeation. Eq.(2), 
instead, is a mass balance stating that, at any time t, the sum 
of the single-stranded DNA oligonucleotide mass present in 
the donor chamber (VdCd), in the membrane () SC XX
L
M d
M () ∫
0  
and in the receiver chamber (VrCr) must be equal to the initial 
(t = 0) single-stranded DNA oligonucleotide mass present in 
the donor chamber when both the membrane and the receiver 
chamber are empty of single-stranded DNA oligonucleotide. 
Assuming that the initial single-stranded DNA oligonucle-
otide concentration in the donor chamber is Cd0, that a linear 
single-stranded DNA oligonucleotide concentration proﬁ  le 
in the membrane holds, and expressing Cd as a function of 
Cr by m s of eq.(2), eq.(1), the model solution is:
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Eq.(3) represents the analytical expression of the ﬁ  rst model.
Although the real physical situation can be more 
complicated by the fact that single-stranded DNA 
oligonucleotide molecules can be in part inside the particles 
and, in part, adsorbed on to particle surfaces (particularly true 
for nanoparticles), the main hypotheses of the second model 
rely on the assumption that all particles are characterized by 
the same initial mean radius R0 and that single-stranded DNA 
oligonucleotide release from particles occurs according to a 
pure particle erosion mechanism. In particular, we assume 
that particle radius R declines according to a linear law:
 
Rt R b t ()=− 0   (4)
where b is the erosion velocity. Accordingly, if the 
hypotheses of model 1 are always true (thin membrane and 
no single-stranded DNA oligonucleotide interaction with the 
membrane), the second model differential equations are:
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where Cp0 is single-stranded DNA oligonucleotide concentration 
in the particles and Vp is the eroded volume of the Np particles 
present in the donor chamber. Eq.(5) is a kinetics equation 
stating that the time variation of single-stranded DNA oligo-
nucleotide mass in the donor chamber (VdCd) is determined 
by the single-stranded DNA oligonucleotide income due to 
particle erosion () C
V
t
p
p d
d
0  less the amount diffusing through 
the membrane ( ( )). SD
L
kC kC r
M
dd r −  Eq.(6), another kinetics International Journal of Nanomedicine 2006:1(4) 527
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equation, models the increase of the eroded volume and it 
states that it depends on the square of particles radius and, 
consequently (see also eq.(4)), on the square of time. Finally, 
eq.(7) is the new expression of the single-stranded DNA oli-
gonucleotide mass balance that differs from the previous one 
(eq.(2)) only for the presence of particles. Indeed, an additional 
term (( ) ) NC R t pp
4
3
0
3 π  related to the amount of single-stranded 
DNA oligonucleotide still present inside the particles at time t, 
appears in eq.(7), left hand side. Finally, the total amount of 
single-stranded DNA oligonucleotide must be always equal to 
the amount initially present inside the particles () . () NC R t pp
4
3
00
3 π  
Eqs.(5)–(7) solution, assuming that Cr = Cd = 0 at the beginning 
(t = 0), yields the following analytical solution:
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where Z1, Z2, Z3, Z4, Z5, α, β, and γ are time-independent 
parameters depending on system geometry, initial condi-
tions erosion kinetics parameter, and single-stranded DNA 
oligonucleotide diffusion coefﬁ  cient in the membrane (see 
Appendix for a detailed expression of these parameters). 
Obviously, this second model expression holds until particles 
are not completely eroded (R(t) ≥ 0). Indeed just after particle 
disappearance (it occurs when R = 0; t* = R0/b), the second 
model expression becomes:
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Indeed, for t  t*, the second model identifies with 
the first model as the erosion phenomenon disappears. 
Eqs.(10)–(11) solution, assuming that for t  =  t* 
Ct Ct R b t C rd () ( ) ( )
** * =− − − = αβ γ 0
3
 (see eq.(9)), 
reads:
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where, again, α1, β1, and γ1 are time-independent parameters 
depending on system geometry, initial conditions, erosion 
kinetics parameter, and single-stranded DNA oligonucleotide 
diffusion coefﬁ  cient in the membrane (see Appendix for a 
detailed expression of these parameters).
Results and discussion
Figure 2a reveals that PLGA microparticles are characterized 
by a perfect spherical shape and that diameter ranges between 
12 μm and 2 μm (mean 7–8 μm), conﬁ  rmed by photon correla-
tion spectroscopy (PCS). On the contrary, Figure 2b reveals 
that SA nanoparticles show an ellipsoidal shape, the smaller 
diameter (∼300 nm) being approximately half the longer one 
(∼600 nm). PCS measurements gave a mean nanoparticle 
spherical diameter of 280 nm. Notably, the nanoparticle size 
distribution is much narrow than that for microparticles.
Before studying the release properties of the micro- and 
nanoparticle preparation loaded with single-stranded DNA 
oligonucleotides, we wanted to make sure that the polymers 
used do not signiﬁ  cantly affect human cell viability. For this 
500 nm
Figure 2a SEM image of poly(DL-lactide-co-glycolide) (PLGA) microparticles. 
They are spherical particles of diameter ranging between approximately 8 μm 
and 2 μm.
Figure 2b SEM image of stearic acid (SA) nanoparticles. They are ellipsoidal, 
with the larger diameter (∼600 nm) 2 times the smaller one (∼ 300 nm).International Journal of Nanomedicine 2006:1(4) 528
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purpose, the effects on cell proliferation, a sensible marker of 
cell viability, were explored. Whereas studies dealing with SA 
effect on cell biology have been already reported (Lima et al 
2002), the effect of the combination of chemicals we used to 
prepare the PLGA microparticles is less clear. For this reason, 
we limited the analysis to the effect on cell proliferation of 
PLGA microparticles. As target cells we used human CSMC, 
known to be implicated in vascular pathologies (Grassi et al 
2005), which can beneﬁ  t from the release of NABD by means 
of micro- and nanoparticles loaded with therapeutic molecules 
(Labhasetwar et al 1997). The double staining technique used 
(Dolbeare et al 1983; Grassi et al 2005) allows detection of 
cells in the different phases of the cell cycle as reported in 
the representative experiment of Figure 3 and summarized 
in Figure 4. It is evident that there are no signiﬁ  cant differ-
ences in cell cycle phase distribution in cells treated by PLGA 
nanoparticles compared with controls cells represented by 
cells treated by a liposome commonly used to transfect CSMC 
and non-treated cells. We thus concluded that, limited to this 
fundamental biological parameter, PLGA microparticles do 
not substantially affect cell viability. It should be also added 
that light microscopy inspection of the cells in the differ-
ent treatments did not reveal any signiﬁ  cant difference in 
morphology, further strengthening the concept of the com-
patibility of PLGA microparticles we prepared with CSMC 
biology (data not shown).
We then moved to the evaluation of the release properties 
of the micro- and nanoparticle preparations loaded with the 
single-stranded DNA oligonucleotide, chosen as a proto-
type of NABD. Figure 5, referring to single-stranded DNA 
oligonucleotide permeation, shows the very good agreement 
between experimental data (symbols) and ﬁ  rst model (eq.(3)) 
best ﬁ  t (solid line). This evidence is also statistically proved 
by the huge value assumed by the F value (Draper and Smith 
1966) (F = 53293  FTABULATED(ν1 = 1, ν2 = 87, 0.01) = 6.9). 
This means that ﬁ  rst model hypotheses (thin membrane and 
no plasmid DNA/membrane interactions) are reasonable. 
Model ﬁ  tting, performed assuming unitary values for both 
the partition coefﬁ  cients kd and kr, yields the following value 
for the single stranded DNA oligonucleotide diffusion coef-
ﬁ  cient in the membrane: D = (7.5 ± 0.1)*10−8 cm2/s. Figure 6 
reports the second model (eqs.(9) and (12)) best ﬁ  t (solid line) 
on experimental data (symbols) referring to single-stranded 
DNA oligonucleotide release from PLGA microparticles and 
subsequent permeation through the membrane. Also in this 
case the data ﬁ  tting is good, as also proved by the huge F 
value (F = 10555  FTABULATED(ν1 = 1, ν2 = 69, 0.01) = 6.9). 
In order to get a more reliable evaluation of the model ﬁ  tting 
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Figure 3 Cell cycle phase distribution. Cell cycle phase distribution was evaluated 
for non-treated human coronary smooth muscle cells (CSMC) (A), CSMC treated 
by a commonly used transfection reagent (B), and poly(DL-lactide-co-glycolide) 
(PLGA) microparticles (C). Cell cycle phase distribution was performed by a DNA 
double staining DNA procedure which enables determination of the amount of total 
DNA/per cell (reported on the abscissa as FL3-A) and the amount of newly synthe-
sized DNA (reported on the ordinates as FL2-H). Based on these measurement it 
is possible to calculate the amount of cells in the different phases of the cell cycle as 
reported in each panel. G1/G0 = cells in the initial phase of cell cycle; S = cells synthe-
sizing new DNA; G2-M = cells in the process of division (cytokinesis). No substantial 
differences were detected among the different treatments.International Journal of Nanomedicine 2006:1(4) 529
Nucleic acids delivery from microparticles and nanoparticles
parameters (D and b), initial D value is assumed equal to that 
previously determined in the single-stranded DNA oligo-
nucleotide permeation experiment ((7.5 ± 0.1)*10−8 cm2/s) as, 
in our hypotheses, D should not be inﬂ  uenced by the erosion 
phenomenon taking place in the donor chamber. Additionally, 
the initial b value is deduced on the basis of the data shown 
in Figure 7. This ﬁ  gure shows the reduction in mean PLGA 
microparticle diameter in PBS, 37°C, in zero shear conditions 
(evaluated by PCS). Although the reduction is not exactly 
linear, rough b estimation can be performed by calculating 
the ratio between radius reduction and time needed for this 
decrease. This leads to b = 2*10−9 cm/s. On the basis of these 
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Figure 4 Summarized cell cycle phase distribution data. Cell cycle phase distribution was evaluated for non-treated cells human coronary smooth muscle cells (CSMC), 
CSMC treated by a commonly used transfection reagent (liposome), and poly(DL-lactide-co-glycolide) (PLGA) microparticles. Data are reported as means ± SD (n=3). No 
statistically signiﬁ  cant differences were noted among the different treatments.
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Figure 6 Comparison between experimental data (open circles) referring to 
single-stranded DNA oligonucleotides release from poly(DL-lactide-co-glycolide) 
(PLGA) microparticles and subsequent permeation through the synthetic 
membrane and model best ﬁ  tting (eq.(9) – (12), solid line). Cr indicates single-
stranded DNA oligonucleotides concentration in the receiver chamber.
Figure 5 Comparison between experimental data (open circles) referring 
to single-stranded DNA oligonucleotides permeation through the synthetic 
membrane and model best ﬁ  tting (eq.(3), solid line). Cr indicates single stranded 
DNA oligonucleotides concentration in the receiver chamber.International Journal of Nanomedicine 2006:1(4) 530
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values, model data ﬁ  tting yields D = (1.0 ± 0.05)*10−7 cm2/s 
and b = (3.6 ± 0.3) 10−8 cm/s. Although statistically differ-
ent, this value for the single-stranded DNA oligonucleotide 
diffusion coefﬁ  cient is close to that previously determined, 
as the difference is below 30%. On the contrary, a one order 
of magnitude difference exists between b value evaluated 
according to second model best ﬁ  t and that estimated on the 
basis of PLGA microparticle erosion (see Figure 7). Never-
theless, due to the difﬁ  culty of exactly recreating the same 
hydrodynamic conditions in both cases, we can accept this 
discrepancy. It is worth mentioning that, according to this 
data ﬁ  tting, complete particle erosion takes 10555 s (= t*) 
and this corresponds to single-stranded DNA oligonucle-
otide concentration in the receiver environment equal to 
approximately 0.22 μg/cm3. This means that up to 10555 s, 
eq.(9) holds, then eq.(12) holds. Qualitative experimental 
observations veriﬁ  ed that after around 10000 s, particle 
volume was greatly reduced although complete particle 
disappearance did not occur. This discrepancy with model 
prediction can be explained by remembering that our model 
assumes all particles were equal (same diameter) and per-
fectly spherical. If microparticles are really spherical, they 
do not constitute a perfect mono-disperse particles ensemble 
as shown in Figure 2a. Bigger particles require a more time 
for complete dissolution.
In ﬁ  tting single-stranded DNA oligonucleotide release 
from SA nanoparticles and subsequent permeation, initial D 
value was ﬁ  xed to (7.5 ± 0.1)*10−8 cm2/s and initial b value 
was assumed to be 2*10−9 cm/s, as we did in the PLGA 
microparticles case. Indeed, theoretically, D should be the 
same in all the release tests performed. Unfortunately, as 
nanoparticle dimensions prevented a reliable experimental b 
determination, unlike microparticles, we decided to assume 
the value for microparticle erosion. Figure 8 clearly shows 
that in this case data ﬁ  tting is more than satisfactory and this 
assumption is statistically supported by the huge F value 
(F = 31647 >> FTABULATED(ν1 = 1, ν2 = 87, 0.01) = 6.9). Fitting 
parameters gave D = (1.5 ± 0.1)*10-7 cm2/s and b = (2.8 ± 
0.2)x10−9 cm/s. Also, in this case the single-stranded DNA 
oligonucleotide diffusion coefﬁ  cient is bigger (two fold) 
than that evaluated in the permeation experiment and that 
evaluated in the microparticle erosion/permeation experiment 
(exceeded by 50%). This evidence let us conclude that the 
single-stranded DNA oligonucleotide diffusion coefﬁ  cient 
in our synthetic membrane is around 10−7 cm2/s. In addition, 
data ﬁ  tting reveals that the SA nanoparticle erosion is one 
order of magnitude smaller than that found for PLGA mic-
roparticles. Thus, theoretically, SA nanoparticles disappear 
after 5360 s (= t*) and, consequently, eq.(9) holds at up to 
5360 s, and then eq.(12) holds. Also in this case, qualitative 
experimental observations veriﬁ  ed that after around 5000 s, 
particle volume was greatly reduced although a complete 
particle disappearance did not occur. This discrepancy with 
model prediction can be explained by remembering that our 
nanoparticles are not perfectly spherical (see Figure 2b), as 
required by the model.
The fact that nanoparticle erosion is smaller than that of 
microparticle erosion could be relevant in the optimization 
of NABD delivery from micro- and nanoparticles. Indeed, in 
relation to a particular pathology, the desired NABD release 
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Figure 8 Comparison between experimental data (open circles) referring to single 
stranded DNA oligonucleotides release from SA nanoparticles and subsequent 
permeation through the synthetic membrane and model best ﬁ  tting (eq.(9) – (12), 
solid line). Cr indicates single-stranded DNA oligonucleotides concentration in the 
receiver chamber.
Figure 7 poly(DL-lactide-co-glycolide) (PLGA) microparticle diameter decrease 
in zero shear conditions (PBS, 37°C). Measures were performed by photon 
correlation spectroscopy.International Journal of Nanomedicine 2006:1(4) 531
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rate can be reached by properly selecting particle dimensions 
(size distribution) and composition.
Conclusions
In this paper we developed an experimental and theoretical 
approach to clarify how NABD can be released from PLGA 
microparticles and SA nanoparticles in zero shear conditions. 
This situation can be experienced in some delivery situations 
such as those found in trans-dermal release and the in situ 
release to organ parenchyma. Attention was focused on the 
evaluation of the possible toxic effects on cell biology for 
only PLGA microparticles, as investigations already exist 
for the effects of SA on cell biology (Lima et al 2002). For 
NABD release from PLGA microparticles and SA nanopar-
ticles, experimental evidence and the theoretical interpreta-
tion of the data lead to the conclusion that NABD release 
from PLGA microparticles and SA nanoparticles in zero 
shear conditions is perfectly compatible with a pure particle 
erosion mechanism. In addition, the release kinetics strongly 
depend on the material constituting the particles. We also 
found that PLGA microparticle erosion is, approximately, 
one order of magnitude higher than that for SA nanoparticles. 
These data suggest that a proper balance between small 
and big particles, eventually of different materials, can be 
used to obtain the delivery kinetics suitable for the speciﬁ  c 
application. Finally, to evaluating the possible toxic effects 
of PLGA microparticles on cell biology, we could not show 
any detectable negative effects, at least on cell proliferation 
and cell morphology, two pivotal biological parameters.
In conclusion, we believe that the reported observations 
can can help optimize delivery systems aimed at release of 
NABD from micro- and nanoparticles, which have applica-
tions in many in situ delivery conditions.
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Appendix
Assuming that a linear concentration proﬁ  le instantaneously develops inside the membrane, the integral appearing in eq.(7) 
becomes:
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Accordingly, eq.(7) can be used to express Cr in function of R(t) and Cd(t):
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Inserting eq.(14) into eq.(5) gives the following differential equation:
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Imposing that Cd = 0 for t = 0, eq.(16) solution reads:
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Cr temporal evolution is then given by eq.(9) or (14).
For t  t* (= R0/b), eq.(8) and (14) do not longer hold and model solution is given by solving eq.(10) and (11):
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Inserting eq.(13) into eq.(10), it is possible to express Cd as a function of Cr:
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Inserting eq.(20) into eq.(10) leads to:
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Imposing that, for t = t*, CC C t rr d - == ( )
** , αβ  eq.(21) solution is given by eq.(12):
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